anti-IL4Ralpha/anti-IL-5 bispecific antibody (argenx)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-IL4Ralpha/anti-IL-5 bispecific antibody (argenx)
Drug Alias Namebispecific antibody targeting multiple type 2 cytokines (argenx)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-4 receptors inhibitorsInterleukin-5 inhibitors
TargetsInterleukin-4 receptorsInterleukin-5
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArgenx Se
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArgenx Se
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A